Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.46 · Revenue $206.80M · 10 analysts
Est. EPS $0.58 · Revenue $222.33M · 10 analysts
Est. EPS $2.06 · Revenue $827.45M · 11 analysts
Est. EPS $0.58 · Revenue $223.84M · 8 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $738.3M | +16.4% | +5.1% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $48.9M | +291.6% | -39.9% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +47.1% | +8.8% | +4.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +8.1% | +245.8% | -36.9% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +6.6% | +264.7% | -42.8% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $93.9M | -34.1% | +18.5% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +12.7% | -43.4% | +12.8% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 32.8% | -5.8% | +0.2% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 8.37x | -0.4% | -1.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $2.9B | +4.2% | +0.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 0.86 vs 1.66 | -48.3% | 0.09 vs 0.46 | -80.5% |
| Revenue Surprise | $738.3M vs $733.1M | +0.7% | $204.1M vs $206.8M | -1.3% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Hughes Violetta | officer: CHIEF ACCOUNTING OFFICER | Common Stock | D | 277 | $170.02 |
| Aug 20, 2026 | Loeillot Olivier | director, officer: Chief Executive Officer | Common Stock | A | 5,426 | $141.79 |
| Aug 20, 2026 | Loeillot Olivier | director, officer: Chief Executive Officer | Common Stock | D | 5,426 | $180.00 |
| Aug 20, 2026 | Loeillot Olivier | director, officer: Chief Executive Officer | Stock Option (Right to Buy) | D | 5,426 | $141.79 |
| Jul 16, 2026 | Garland Jason K | officer: CFO | Common Stock | D | 530 | $150.00 |
Jacob Johnson: And we'll provide financial guidance for the full year 2026. Join us on the call today are Repligen's President and Chief Executive Officer, Olivier Leo; and our Chief Financial Officer, Jason Garland. As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risks related to our business is included in our quarterly reports on Form 10-Q, our annual report on Form 10-K, our current reports, including the Form 8-K that we are filing today and other filings that we make with the Securities and Exchange Commission. Today's comments reflect management's current views, which could change as a result of new information, future events or otherwise. The company does not oblig or commit itself to update forward-looking statements, except as required by law. During this call, we are providing non-GAAP financial results and guidance, unless otherwise noted. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen's website and on sec.gov. Adjusted non-GAAP figures in today's report include the following: organic revenue and/or revenue growth, cost of goods sold, gross profit and gross margin; operating expenses, including R&D and SG&A, income from operations and operating margin, other income or expense, tax rate on pretax income, net income, diluted earnings per share, EBITDA, adjusted EBITDA and adjusted EBITDA margin. These adjusted financial measures should not be viewed as an alternative to GAAP measures, but are intended to best reflect the performance of our ongoing operations. With that, I'll turn the call over to Olivier. Olivier Loeillot: Thank you, Jacob. Good morning, everyone, and welcome to our 2026 first quarter call. We are delighted to share our first quarter 2026 results. Great execution once again by our team enabled us to deliver 15% reported revenue growth or 11% organic and 160 basis points of adjusted operating margin expansion. Mid-teens top line growth, coupled with disciplined cost management resulted in margins outperforming expectations. In addition to our strong financial performance in the quarter, we advanced several key strategic priorities. This includes the launch of our transformation office, the associated sale of the polymer business and a new partnership in China. This OEM relationship advances our strategy in the country where we are seeing significant growth again. I'll touch on each of these initiatives in more detail shortly. As I reflect on our end markets and company today, it's encouraging to see the strength we are seeing across all of our customer segments. The talented and experienced team we have assembled is executing fiercely on our differentiated strategy. …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Olivier Loeillot | President, Chief Executive Officer & Director | USD 1,644,292 | Male | 1970 | Active |
Jason K. Garland | Chief Financial Officer & Chief Compliance Officer | USD 1,001,686 | Male | 1974 | Active |
James R. Bylund | Chief Operating Officer | USD 856,048 | Male | 1963 | Active |
Ralf Kuriyel | Senior Vice President of Research & Development | USD 749,108 | Male | 1958 | Active |
Anthony J. Hunt | Advisor | USD 671,000 | Male | 1964 | Active |
Brian Douglass | Senior VP & Chief Product Officer | USD 638,106 | Male | 1975 | Active |
Heather Ems | Chief Information Officer | — | Female | — | Active |
George Scott Jr. | Senior VP & General Counsel | — | Male | — | Active |
Jacob K. Johnson | Vice President of Investor Relations | — | Male | — | Active |
Neil Whitfield | Senior Vice President of Sales | — | Male | — | Active |
Violetta Hughes | Chief Accounting Officer | — | Female | 1973 | Active |
Avidity Partners Management LP increased its position in shares of Repligen Corporation (NASDAQ: RGEN) by 54.7% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,800 shares of the biotechnology company's stock after acquiring an additional 27,500
The consensus price target hints at a 25.7% upside potential for Repligen (RGEN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
RGEN tops Q2 earnings and revenue estimates, lifts its 2026 revenue and EPS outlook, and sees shares jump after stronger-than-expected results.
Repligen Corporation (RGEN) Q2 2026 Earnings Call Transcript
Repligen NASDAQ: RGEN reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted earnings outlook, citing continued order momentum and improved visibility into the second half.
